Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017248 | 0.84 | ERN1 (0.52) | ERN1CYP2A6ALDH1A1PTPN1PRKDC | |
| SCHEMBL31050324 | 0.84 | ERN1 (0.52) | ERN1CYP2A6ALDH1A1PTPN1PRKDC | |
| SCHEMBL9952004 | 0.79 | ERN1 (0.43) | ERN1CYP2A6ALDH1A1PTPN1PRKDC | |
| SCHEMBL27993122 | 0.79 | ERN1 (0.43) | ERN1CYP2A6ALDH1A1PTPN1PRKDC | |
| SCHEMBL22867745 | 0.79 | ALDH1A1 (0.44) | ERN1CYP2A6ALDH1A1LMNAPIM3 | |
| SCHEMBL2800253 | 0.78 | ALDH1A1 (0.48) | ALDH1A1LMNA | |
| SCHEMBL3376315 | 0.78 | ALDH1A1 (0.48) | CYP2A6ALDH1A1 | |
| SCHEMBL362934 | 0.76 | ALDH1A1 (0.42) | ERN1ALDH1A1PTPN1 | |
| SCHEMBL4866236 | 0.76 | TDP1 (0.55) | ERN1ALDH1A1PTPN1CCR2 | |
| SCHEMBL29954894 | 0.76 | TYR (0.43) | ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| CN-107873031-A | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-04-03 | — | — | CN | disclosed |
| WO-2017193016-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | MELINTA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2014122160-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2007002563-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | ERN1 2205/4885CYP2A6 176/4885ALDH1A1 3198/4885 |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | ERN1 1420/4885CYP2A6 81/4885ALDH1A1 2042/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | ERN1 1427/4885CYP2A6 2721/4885ALDH1A1 2034/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | ERN1 1427/4885CYP2A6 2721/4885ALDH1A1 2034/4885 |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | ERN1 1680/4885CYP2A6 1147/4885ALDH1A1 109/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | ERN1 1427/4885CYP2A6 2721/4885ALDH1A1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.